In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Astellas Pharma, Inc.

http://www.astellas.com

Latest From Astellas Pharma, Inc.

Big In Japan: Assessing Seven Years Of Sakigake

Japan’s fast-track approval system for innovative drug candidates has marked its seventh year since launch, during which it has accepted 27 candidates with 13 of these moving to approval. But in recent years the system has faced a decreasing number of admitted candidates, this original infographic analysis shows.

Japan Review Pathway

Twist's Unconventional Approach, Adding Value One Rung At A Time

Building a narrow set of products and services that provide reliable and consistent revenue is a perfectly sound business strategy and one that sustains many biotech companies. But for the hungrier, like Twist Bioscience, Inc., a strategy of ongoing disruption and evolution has been more appealing and indeed is generating significant growth. Emily Leproust, Twist’s CEO, spoke with In Vivo about what it means to follow a value-added business strategy.

Business Strategies Commercial

Stock Watch: Wrap Up For The Biotech Winter

A drastic risk-off pullback in the public market can close an IPO window while private biotechs aspiring for either a public debut or an acquisition by big pharma may be stymied by their stale valuations.

Stock Watch M & A

RWE’s Biggest Role In US FDA Approvals: External Controls For Breakthrough Rare Disease Therapies

Despite broad interest, real-world evidence of efficacy in FDA decisions remains largely limited to orphan diseases and natural history, a Pink Sheet analysis shows.

Real-World Evidence Rare Diseases
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Advanced Cell Technology, Inc.
    • Agensys, Inc.
    • Audentes Therapeutics, Inc.
    • Fujisawa GmbH
    • Ganymed Pharmaceuticals AG GmbH
    • iota Biosciences
    • Mytogen, Inc.
    • Nanna Therapeutics Limited
    • Perseid Therapeutics LLC
    • Potenza Therapeutics Inc.
    • Ocata Therapeutics, Inc.
    • OSI Pharmaceuticals, LLC (Cell Pathways
    • Prosidion)
    • Yamanouchi Pharmaceutical Co., Ltd.
    • Ogeda S.A.
    • Mitobridge, Inc.
    • Mitokyne, Inc.
    • Quethera Limited
    • Universal Cells, Inc.
    • Xyphos Biosciences, Inc.
UsernamePublicRestriction

Register